Date of publication: February 23,
2006
Source:
http://gmoinfo.jrc.it/gmp_browse_geninf.asp
Notification number: B/ES/06/31
Member State:Spain
Date of Acknowledgement:24/01/2006
Title of the Project:
Testing of genetically modified 1507x59122
(DAS-Ø15Ø7-1xDAS-59122-7) maize.
Proposed period of release From:01/04/2006
To:31/12/2009
Name of the Institute(s) or Company(ies): PIONEER
HI-BRED SPAIN S.L.;
3. Is the same GMPt release planned elsewhere in the
Community?
No
4 - Has the same GMPt been notified elsewhere by the same
notifier?
No
Genetically
modified plant
1. Complete name of the
recipient or parental plant(s)
|
Common Name
|
Family Name
|
Genus |
Species
|
Subspecies
|
Cultivar/breeding line
|
| maize
|
poaceae |
zea
|
zea
mays |
mays
|
Experimental varieties |
2. Description of the traits and characteristics which have
been introduced or modified, including marker genes and previous
modifications:
The genetically modified 1507x59122 maize varieties that will
be tested in these field trials are resistant to certain
Lepidopteran insects, such as the European corn borer (Ostrinia
nubilalis) and to certain Coleopteran insects, such as the
Western corn rootworm (Diabrotica virgifera virgifera), and
tolerant to glufosinate-ammonium herbicide. This maize was
derived through traditional breeding methods between progeny of
genetically modified 1507 maize, which is resistant to certain
lepidopteran insects and tolerant to glufosinate herbicide, and
59122 maize, which is resistant to certain coleopteran insects
and tolerant to glufosinate herbicide.
Genetic
modification
3. Type of genetic
modification:
Insertion;
4. In case of insertion of genetic material, give the source
and intended function of each constituent fragment of the region
to be inserted:
The genes introduced in 1507x59122 maize are the cry1F gene
from Bacillus thuringiensis var. aizawai, providing resistance
to certain Lepidopteran insects and the pat gene from
Streptomyces viridochromogenes, introduced as a selectable
marker, providing tolerance to glufosinate-ammonium herbicide,
like in 1507 maize, and the cry34Ab1 and cry35Ab1 genes from
Bacillus thuringiensis strain PS149B1, providing resistance to
certain Coleopteran insects and the pat gene from Streptomyces
viridochromogenes, introduced as a selectable marker, providing
tolerance to glufosinate herbicide, like 59122 maize, along with
their regulatory components necessary for expression in maize
plant:
- the cry1F gene, the UBIZM1(2) promoter, the ORF25PolyA
terminator.
- the pat gene, the CaMV35S promoter, the CaMV35S terminator.
- the cry34Ab1 gene, the UBIZM1(2) promoter, the PINII
terminator.
- the cry35Ab1 gene, the Peroxidase promoter, the PINII
terminator.
- the pat gene, the CaMV35S promoter, the CaMV35S terminator.
6. Brief description of the method used for the genetic
modification:
No genetic modification was made on the 1507x59122 maize
directly: it was derived through traditional breeding methods
between progeny of the genetically modified 1507 and 59122
maize.
1507 maize was genetically modified using a particle
acceleration method, 59122 maize was genetically modified using
Agrobacterium transformation method.
7. If the recipient or parental plant is a forest tree
species, describe ways and extent of dissemination and specific
factors affecting dissemination:
Not applicable.
Experimental
Release
1. Purpose of the release:
The purpose of the release is the testing of genetically
modified 1507x59122 maize varieties in view of collecting
regulatory data for registration on the National Catalogue of
varieties.
2. Geographical location of the site:
The release is planned at the following locations in Spain in
2006:
- Andalucía: La Rinconada (Sevilla), Marchena (Sevilla)
- Aragón: Zuera (Zaragoza), Gelsa (Zaragoza), Gurrea de Gállego
(Huesca)
- Castilla-León: Toro (Zamora), Llamas de la Ribera (Leon),
Pelabravo (Salamanca)
- Cataluña: Alguaire (Lérida)
- Castilla la Mancha: Membrilla (Ciudad Real), Tarazona de la
Mancha (Albacete), Alpera (Albacete)
- Galícia: Santa Uxía de Ribeira (La Coruña), Mesía (La Coruña)
- Madrid: San Martín de la Vega (Madrid).
- Navarra: Cortes (Navarra)
3. Size of the site (m2):
In 2006, each site could have up to 1000m² sown with the
genetically modified maize subject of this notification
(1507x59122 maize), the total trial surface (all varieties and
borders included) being larger.
In the following years, there could have up to 1000m² of the
genetically modified maize subject of this notification
(1507x59122 maize) sown per site, the total trial surface at
each site (all varieties and borders included) being larger.
4. Relevant data regarding previous releases carried out with
the same GM-plant, if any, specifically related to the potential
environmental and human health impacts from the release:
Field trials have already been conducted at different
locations across maize growing regions in North America, South
America and Europe, and no environmental problems were reported
for these trials. The transgenic maize plants were
indistinguishable from the non-genetically modified maize plants
except for showing resistance to certain Lepidopteran insects,
such as European corn borer, and to certain Coleopteran insects,
such as Western corn rootworm, and showing tolerance when
glufosinate herbicide was applied, traits due to the genetic
modifications.
Environmental
Impact and Risk Management
Summary of the potential
environmental impact from the release of the GMPts:
No risks to human and animal health or the environment from
the deliberate release of genetically modified maize resistant
to certain Lepidopteran and Coleopteran insects and tolerant to
glufosinate herbicide are expected, as per information contained
in the environmental risk assessment and the following
concluding remarks:
- There is negligible likelihood for 1507x59122 maize to become
environmentally persistent or invasive giving rise to any
weediness;
-Expression of Cry1F, Cry34Ab1, Cry35Ab1 and PAT proteins in
1507x59122 maize does not confer any selective advantage outside
the agricultural environment;
- There are no wild relatives of maize in the EU and the
traditional breeding that led to 1507x59122 maize does not
introduce any selective advantages to maize plants outside
heavily managed agricultural environments;
- The deliberate release of 1507x59122 maize will result in
negligible immediate and/or delayed environmental impact
resulting from direct and indirect interactions of 1507x59122
maize with non-target organisms;
- The genetic modification in 1507x59122 maize does not
introduce any new compounds known to cause, or expected to
cause, any potential immediate and/or delayed effects on human
health. Moreover, 1507x59122 maize subject of the release will
not enter the food chain;
- The genetic modification in 1507x59122 maize does not
introduce any new compounds known to cause, or expected to
cause, any possible immediate and/or delayed effects on animal
health. Moreover, 1507x59122 maize subject of the release will
not enter the feed chain;
- The 1507x59122 maize will not cause any possible immediate
and/or delayed effects on biogeochemical processes;
- The specific cultivation, management and harvesting techniques
used for the 1507x59122 maize are identical to those used for
non-genetically modified maize, with the exception of the
herbicide regime and monitoring plan to be proposed for
commercial cultivation of 1507x59122 maize;
- The potential reduction of the control of certain lepidopteran
and coleopteran insect pests if the target insect pests develop
resistance to the Cry1F, Cry34Ab1 or Cry35Ab1 proteins as
expressed in 1507x59122 maize has been identified as the only
potential risk resulting from the interaction of 1507x59122
maize with target organisms. In the case of the trials, the
likelihood of the occurrence of this potential identified
adverse effect is negligible. The risk posed by the
target-insect resistance development is thus negligible.
However, an IRM strategy will be developed in the context of
product stewardship for the placing on the market of 1507x59122
maize.
Brief description of any measures taken for the management of
risks:
The shedding of pollen from the genetically modified plants
will be controlled by maintaining a 200-meter isolation distance
with any other non-experimental maize crop. In addition, the
trial site will be surrounded by four border rows of
conventional maize of a similar relative maturity that will be
also destroyed at the end of the release.
Seed dispersal of individual kernels does not generally occur.
They are fixed on a cob and enclosed in many husks that protect
the seeds from outside contact. When a few seeds need to be
collected for analysis; this will be done by sampling the whole
ear and unused seeds will be destroyed.
In case of any emergency, the trial could be stopped by
application of a non-selective herbicide other than glufosinate
or by mechanical destruction, and incorporation into the soil.
At the end of the release, all remaining plant matter that has
not been harvested for analyses will be destroyed by chopping
and incorporating into the soil. No plant or plant product
coming from the trials will enter the food or feed chains.
Volunteer maize will be monitored during the following year. An
herbicide treatment (other than glufosinate) will be used in
order to ensure destruction if needed.
There will be no commercial maize grown on the same field the
following year.
Summary of foreseen field trial studies focused to gain new
data on environmental and human health impact from the release:
Not applicable to this release.
Final report
-
European
Commission administrative information
Consent given by the Competent
Authority: Not Known |
